| Document |
Document Title |
|
WO/2015/085173A1 |
The invention comprises compounds, methods of making, and methods of using. The compounds may have a linear or cylic backbone and three or four appended functional groups: one or two lipohilic compounds including sterols or "fat soluble"...
|
|
WO/2015/083561A1 |
The purpose of the present invention is to provide a disaccharide compound which can be optimally used to obtain a modified organopolysiloxane compound having excellent surface-active action. A further purpose is to provide a modified or...
|
|
WO/2015/081438A1 |
It is provided a multivalent gangloside carbohydrate as a therapeutic cancer vaccine. The GD2 and GD3 carbohydrate conjugated disclosed are linked by a spacer to form a multimer which conserves the native structural feature of naturally ...
|
|
WO/2015/067926A1 |
Chromogenic substrates for β-D-glucuronidase activity comprising monoglucuronides of some 1,2-dihydroxyaromatic derivatives. When cleaved these form soluble coloured conjugates with multivalent metal ions such as iron ions. The substrat...
|
|
WO/2015/067927A1 |
Conjugates of 2,3-dihydroxynaphthalene and its derivatives with enzyme cleavable groups are chromogenic substrates that form coloured compounds when complexed with metal ions, e.g. iron ions, on cleavage by enzymes, and are useful in mic...
|
|
WO/2015/051454A1 |
The present invention relates to nucleotide sequences encoding ent-kaurenoic acid 13- hydroxylase polypeptides and polypeptides having ent-kaurenoic acid 13-hydroxylase activity. The invention also relates to methods of producing steviol...
|
|
WO/2015/050240A1 |
The present invention provides a novel organic acid glycoside that is present in coffee beans and a use thereof. Provided is a compound having a structure represented by formula (1) [in the formula, R1-R7 are each selected independently ...
|
|
WO/2015/043511A1 |
Disclosed are glucopyranosyl derivatives used as sodium dependent glucose cotransporters (SGLTs) inhibitors, intermediates or preparation processes thereof, and pharmaceutical uses thereof, especially glucopyranosyl derivatives represent...
|
|
WO/2015/046183A1 |
The purpose of the present invention is to provide a glycoamino acid which is an amino acid precursor having improved properties (particularly solubility in water, stability in water, bitterness, etc.). The present invention relates to a...
|
|
WO/2015/048616A1 |
Methods for treating and/or preventing mucositis comprising administering to a subject in need thereof an effective amount of at least one compound chosen from E-selectin antagonists, pharmaceutically acceptable salts of E-selectin antag...
|
|
WO/2015/028548A1 |
Disclosed is tri- or tetravalent sialic acid derivatives comprising a core moiety to which 3 or 4 sialic acid residues are connected via a linker. Such derivatives inhibit the binding of adenovirus to human cells, whereby infections, suc...
|
|
WO/2015/023928A1 |
Sweetener compositions including at least 3% Rebaudioside N by weight based on the total weight of sweetener compounds in the sweetener composition are disclosed. The sweetener compositions are used to prepare sweetened compositions incl...
|
|
WO/2015/020114A1 |
Provided is a novel sophorolipid (SL) that can be applied in a wide range of fields such as beverages, cosmetics, drugs, and quasi-drugs. This sophrolipid compound is represented by formula (I) (in formula (I), R1 represents H or a methy...
|
|
WO/2015/019193A2 |
The present specification is directed to an acylated flavonoid derivative derived from natural or synthetic flavonoids and fatty acids. The acylated flavonoid derivatives can be part of a pharmaceutical composition. Method of decreasing ...
|
|
WO/2015/020051A1 |
[Problem] The purpose of the present invention is to provide a method for extracting ceramide and/or pectin, which are useful components, from whole apples and/or apple juice residue. Another purpose of the present invention relating to ...
|
|
WO/2015/014959A1 |
The present invention relates a process for the recovery of one or more steviol glycosides from a steviol glycoside-containing fermentation broth, which method comprises (a) providing a fermentation broth comprising one or more steviol g...
|
|
WO/2015/011517A1 |
The present invention provides novel processes for the preparation of Fondaparinux sodium by using the compound of formula ABC5. In some embodiments, the intermediates for the synthesis of Fondaparinux sodium, are also provided.
|
|
WO/2015/012110A1 |
The purpose of the present invention is to provide a technique for manufacturing a C-glycoside derivative with high efficiency and in commercially advantageous conditions. A C-glycoside derivatives can be manufactured in a short period o...
|
|
WO/2015/011441A1 |
The invention provides methods and materials for use in the detection of influenza viruses which utilise a nanoparticle, for example gold nanoparticule, probe comprising a plurality of glycoconjugate ligands, each glyconjugate ligand (GL...
|
|
WO/2015/008007A1 |
The invention relates to novel solanidine-derived compounds, the synthesis method thereof and the uses of same in the fields of phytosanitary protection and health. In particular, the invention relates to novel compounds having toxic and...
|
|
WO/2015/006763A1 |
Sweetened compositions comprising at least one sweetener and rebaudioside X are provided herein. Rebaudioside X is present in the sweetened compositions in a concentration at or below the sweetness recognition threshold, while the at lea...
|
|
WO/2015/004041A1 |
The present invention relates to the total synthesis of saccharide structures contained in the capsular polysaccharide of Streptococcus pneumoniae type 1, to glycoconjugates containing said saccharide structures obtained by total synthes...
|
|
WO/2012/132022A9 |
Provided is a compound represented by the formula (I): wherein R1 represents R5=N- (R5 represents a saccharide residue) or (R4 represents a mono- or polyethylene glycol residue); each of R2 and R3, whether identical or not, represents a ...
|
|
WO/2015/006764A1 |
Rebaudioside M compositions with improved aqueous solubility and methods for preparing the same are provided herein. The rebaudioside M compositions include (i) disordered crystalline compositions comprising rebaudioside M and rebaudiosi...
|
|
WO/2015/000132A1 |
The present invention provides a method for preparing epirubicin and an intermediate thereof related to the method. The preparation method may comprise: reacting tert-Butyldimethylsilyl chloride with N-trifluoroacetyl adriamycin to obtai...
|
|
WO/2015/000792A1 |
The current invention is directed towards mixtures of compounds, comprising (A) in the range of from 93 to 97 % by weight compound of general formula (I) (B) in the range of from 3 to 6.5 % by weight compound of general formula (II) (C) ...
|
|
WO/2014/206299A1 |
Disclosed in the present invention is a method for preparing a liflozin drug intermediate using a microreactor, comprising: mixing compound III dissolved in an organic solvent with an organometallic reagent in a microreactor unit (L) by ...
|
|
WO/2014/203887A1 |
In the present invention, by applying a solution containing the fullerene represented by formula (1) to a substrate and firing at 450°C or higher, an n-type organic semiconductor thin film that has favorable ionization potential and has...
|
|
WO/2014/204866A1 |
The present disclosure provides mixtures of prenylated flavonoids, stilbenes, or both with flavans or curcuminoids or both capable of modulating joint inflammation, joint pain, joint stiffness, cartilage degradation, or improving mobilit...
|
|
WO/2014/200363A1 |
The invention relates to sphingoglycolipid analogues which are useful in treating or preventing diseases and conditions such as those relating to infection, atopic disorders, autoimmune diseases or cancer.
|
|
WO/2014/200964A1 |
The invention relates to processes for preparing (S,S)-secoisolariciresinol diglucoside and (R,R)-secoisolariciresinol diglucoside and compositions comprising the same.
|
|
WO/2014/196887A1 |
Derived for the first time are individual (without the addition of penta- and hexa-acyl derivatives) di-, tri- and tetra-acyl S-LPS of endotoxic bacteria and combinations thereof, and the immunobiological, physicochemical and chemical...
|
|
WO/2014/195828A1 |
The present invention relates to a novel method for synthesising, without a solvent, N-alkyl-glycosyl(di)amine derivatives represented by the following general formula (I): The invention also concerns the use of N-alkyl-glycosyl(di)amine...
|
|
WO/2014/196861A1 |
A fructoside-containing product is manufactured from a glucose-rich feedstock, in a process wherein glucose to fructose is isomerized by contacting the glucose-rich feedstock with a basic isomerization catalyst in an alcoholic medium at ...
|
|
WO/2014/193856A1 |
A method for the development of a library of modified sophorolipids using a wide- range of chemical and enzyme catalyst tools to identify modified sophorolipids that can be used in pure form, as mixtures with other modified sophorolipids...
|
|
WO/2014/193183A1 |
The present invention relates to a method for preparing a sialic acid derivative, wherein the method is characterized in that a process of using N-acetyl-D-glucosamine to prepare CMP-M-acetylneuraminic acid and a process of combining sia...
|
|
WO/2014/192848A1 |
It was discovered that an arbekacin derivative containing arbekacin carbonate and a carbamate of arbekacin can be produced by adding carbon dioxide or the like to a solution containing arbekacin free base. It was also discovered that thi...
|
|
WO/2014/190024A1 |
The invention concerns compounds of the formula (I) wherein: Y1 and Y2 are independently a monosaccharide or disaccharide; X1 and X2 are independently -(R9-O)m-, -(R10)P-, -O-(R11-O)q-, -R16-O-R17-O- or a covalent bond; Q1 and Q2 are ind...
|
|
WO/2014/190236A1 |
Embodiments in accordance with the present invention encompass water soluble poiyc-ycHc vinyl addition polymers having a norboraene type repeat unit derived from a norboraene type of monomer that encompasses a saccharide functional moiet...
|
|
WO/2014/187365A1 |
The present invention relates to a oxabicyclo derivative, preparation method and use thereof, specifically to oxabicyclo derivatives shown by general formula (I) or hydrates, solvates, stereoisomers thereof, pharmaceutically acceptable s...
|
|
WO/2014/187464A1 |
The present application discloses a synthetic mixture of oligosaccharides for treating a microbiota of a mammal, preferably a human, to reduce or eliminate the activity and/or the proportion of a microbe in the microbiota that is associa...
|
|
WO/2014/183630A1 |
The present invention provides a compound as represented by formula I, which has a structure as follows: R1 and R2 are glycosyl, R3 is H, hydroxyl or methoxyl; R4 is hydroxyl or methoxyl; and R5 is H, hydroxyl or methoxyl. The present in...
|
|
WO/2014/186027A1 |
Aryl or heteroaryl 1-substituted triazoles are prepared by cyclizing aryl or heteroaryl hydrazines with urea and alkyl orthoformates.
|
|
WO/2014/178195A1 |
The present invention provides an immunity inducer and an immunity inducing method using same. The immunity inducer has an immunopotentiation effect on any target oligosaccharide antigen, in particular oligosaccharide antigens included i...
|
|
WO/2014/173957A2 |
A compound of formula (I) wherein R is a C9-23 polyunsaturated alkenyl group; X is SO3R3, SO2R3, PO3R3, PO2R3, COCHal3, or COOR3; R1 and R2 are each independently H, a C1-6 a iky I group optionally substituted with OH, C6-10 aryl group o...
|
|
WO/2014/167537A1 |
This invention relates to a chemo-enzymatic synthesis of oligosaccharidesof formula 1 wherein R is selected from -OH, -N3 and -OR6 wherein R6 is selected from allyl optionally substituted by one or more methyl, propargyl optionally subst...
|
|
WO/2014/166139A1 |
The present invention relates to a method for synthesizing dibekacin and arbekacin. The method comprises: using kanamycin B as an initial raw material, protecting five amino groups of the kanamycin B by using t-butyloxycarboryl, protecti...
|
|
WO/2014/165107A2 |
The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula (I) The invention also provides processes for making the compounds described herein. Furthermore, the ...
|
|
WO/2014/159211A1 |
An alkenyl glycoside is prepared by reacting a metathesis-derived unsaturated fatty alcohol containing 10 to 30 carbon atoms with either (1 ) a reducible monosaccharide or composition hydrolyzable to a reducible monosaccharide, or (2) a ...
|
|
WO/2014/157635A1 |
The purpose of the present invention is to provide a drug that demonstrates a pharmaceutical effect by having high mobility to the mid-brain and converting to bumetanide in the mid-brain, which is the primary site of epilepsy. The presen...
|
